Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep:3:1-12.
doi: 10.1200/CCI.19.00089.

Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology

Affiliations
Review

Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology

Jia Zeng et al. JCO Clin Cancer Inform. 2019 Sep.

Abstract

Genomic testing has become a part of routine oncology care and plays critical roles in diagnosis, prognostic assessment, and treatment selection. Thus, in parallel, the variety of genomic testing providers and sequencing platforms has grown exponentially. Selection of the best-fit panel for each case can be daunting, with many factors to consider. Among them is whether alteration interpretation and therapy/clinical trial matching are included and/or sufficient. In this article, we review some common commercially available sequencing platforms for the genes and types of alterations tested, samples needed, and reporting content provided. We review publicly available resources for a do-it-yourself approach to alteration interpretation when it is not provided or when supplemental research is needed, along with resources to identify genomically matched treatment options that are approved and/or investigational. However, with both commercially provided interpretation and publicly available resources, there are still caveats and limitations that can stem from insufficient or ambiguous nomenclature as well as from the presentation of information. Use cases in which clinical decision making was affected are discussed. After treatment options are identified, it is important to assess the level of evidence for use within the patient's tumor type and molecular profile. However, numerous level-of-evidence scales have been published in recent years, so we provide a publicly available tool to facilitate interoperability. The level of evidence, along with other factors, such as allelic frequency and copy number, can be used to prioritize treatment options when multiple are identified.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Jia Zeng

Stock and Other Ownership Interests: McKesson, Mylan

Dong Yang

Employment: Molecular Health

Thuy Vu

Employment: Roche

Funda Meric-Bernstam

Honoraria: Sumitomo Group, Dialectica

Consulting or Advisory Role: Genentech, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, Origimed, Xencor, Debiopharm Group, Mersana, Seattle Genetics

Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer, Aileron Therapeutics, Puma Biotechnology, CytomX Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Phfizer, eFFECTOR Therapeutics, AbbVie, Boehringer Ingelheim (I), Guardant Health (Inst), Daiichii Sankyo, GlaxoSmithKline

Speakers Bureau: Chugai Pharmaceuticals

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Level of Evidence (LoE) mapper. The LoE mapper provides an interface for a user to provide a description of the evidence found for use of a therapy within the context of a specified disease harboring a specific biomarker. On the basis of the evidence criteria selected, the LoE scale associated with seven standards is displayed along with a tier which we have defined within this article.

Similar articles

Cited by

References

    1. Rubinstein WS, Maglott DR, Lee JM, et al. The NIH genetic testing registry: A new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 2013;41:D925–D935. - PMC - PubMed
    1. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–430. - PubMed
    1. Nagahashi M, Shimada Y, Ichikawa H, et al. Next-generation sequencing–based gene panel tests for the management of solid tumors. Cancer Sci. 2019;110:6–15. - PMC - PubMed
    1. Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 10.1200/PO.18.00169. - DOI - PMC - PubMed
    1. Gray SW, Hicks-Courant K, Cronin A, et al. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32:1317–1323. - PMC - PubMed

Publication types